No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
|Market Cap||1.1 billion|
|Outstanding Shares||223.9 million|
|Sector Name||Health Care|
|Country Short Name||DE|
|Announcement Earnings||2023-03-31 04:00:00+00:00|
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Please sign up and become a member to view all risk profiles.
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.